Innovative Clinical Biomarkers for SLE and RA: Advancing Autoimmune Diagnostics, Upcoming Webinar Hosted by Xtalks
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform [Yahoo! Finance]
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc. (NASDAQ: XGN) had its "outperform" rating re-affirmed by analysts at William Blair.